$JBIO

6 stories mentioning JBIOUpdated 9d ago

Every FINWIRES story that references JBIO, newest first.

What are analysts saying about JBIO?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on JBIO?

Climb Bio's Phase-1 Data From IgA Nephropathy Trial 'Positive,' Wedbush Says

Climb Bio's (CLYM) data from the first phase of its trial evaluating CLYM116 in patients with IgA nephropathy was "positive," Wedbush analysts said in a Friday note.Analysts said they see favorable risk/reward for Climb Bio's shares as additional phase 1 data will likely be presented at the American Society of Nephrology.Some investors were looking for a more clear-cut "winner" between Climb Bio and Jade Biosciences (JBIO) in their nephropathy clinical trials, Wedbush said.Analysts said they expect the valuation gap between Climb Bio and Jade Biosciences to narrow over time as both agents offer benefits compared with first-gen agents.Wedbush kept its outperform rating and a $25 price target on the stock.Shares of the company were up nearly 8% in Friday trading.Price: $15.75, Change: $+1.16, Percent Change: +7.95%

$CLYM$JBIO

Wire34d ago

Wedbush Adjusts Price Target on Jade Biosciences to $47 From $45, Keeps Outperform Rating

Jade Biosciences (JBIO) has an average rating of buy and mean price target of $45.89, according to analysts polled by FactSet.Price: $22.35, Change: $+0.39, Percent Change: +1.78%

$JBIO

Research90d ago

UBS Initiates Jade Biosciences at Buy With $45 Price Target

Jade Biosciences (JBIO) has an average rating of buy and mean price target of $45.89, according to analysts polled by FactSet.

$JBIO

Wire104d ago

Wedbush Raises Price Target on Jade Biosciences to $45 From $34, Maintains Outperform Rating

Jade Biosciences (JBIO) has an average rating of buy and mean price target of $38, according to analysts polled by FactSet.Price: $18.59, Change: $-2.45, Percent Change: -11.64%

$JBIO

Wire110d ago

Jade Biosciences Says First Participant Dosed in First-in-Human Phase 1 Trial of JADE201

Jade Biosciences (JBIO) said late Tuesday the first participant has been dosed in a first-in-human phase 1 clinical trial of JADE201, an investigational, half-life extended, afucosylated monoclonal antibody.The first-in-human trial is a placebo-controlled study assessing single ascending doses of JADE201 in participants with rheumatoid arthritis, according to a statement.Jade said interim phase 1 data in rheumatoid arthritis anticipated in 2027 are expected to inform indication prioritization across potential autoimmune indications supported by B cell activating factor receptor biology.

$JBIO

Sectors110d ago

Sector Update: Healthcare Stocks Advance Premarket Tuesday

Healthcare stocks were advancing premarket Tuesday, with the iShares Biotechnology ETF (IBB) 0.4% higher and the State Street Health Care Select Sector SPDR ETF (XLV) up 0.2%.Eli Lilly (LLY) has agreed to acquire Curevo, LimmaTech Biologics, and Vaccine Company in deals worth up to nearly $3.83 billion in total, expanding its presence in infectious disease prevention, the company said. Shares of Eli Lilly were up more than 1% pre-bell.Natera (NTRA) stock was up more than 2% after the company said it has upgraded its Panorama non-invasive prenatal test using SNP-informed deep sequencing to improve accuracy in samples with low fetal fraction.Jade Biosciences (JBIO) has dosed the first participant in its phase 2 trial of experimental therapy, JADE101, for immunoglobulin A nephropathy, or IgAN, the drugmaker said. Shares of Jade Biosciences were up more than 5% premarket.

$IBB$JBIO$LLY$NTRA$XLV

Track with the FINWIRES app suite

FolioX

Track JBIO in your portfolio

WheelAI

Analyze JBIO options with the wheel strategy

StockInsider

See market sentiment on JBIO